REGENXBIO Inc.

NASDAQ:RGNX

Biotechnology

Healthcare
$7.26 +1.97%

+$0.16 today

Market cap
$480.05M
Beta
1.03
P/E (TTM)
-1.5
EPS (TTM)
-$5.53
52W Low $5.46High $16.19

Volume 0.70M

Average 1.24M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$123.96M

FY 2025 · Annual

Investing Cash Flow

-$15.87M

FY 2025 · Annual

Financing Cash Flow

$116.77M

FY 2025 · Annual

+26.0% YoY

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income127.84M(280.32M)(263.49M)(227.1M)(193.88M)
Depreciation & Amortization9.56M12.91M17.32M16.22M15.62M
Deferred Income Tax(1.92M)0000
Stock-Based Compensation38.81M40.79M40.27M38.46M34.56M
Change in Working Capital40.22M13.98M(10.89M)5.53M11.78M
Accounts Receivables14.12M4.82M3.94M9.71M(7.66M)
Inventory29.3M0000
Accounts Payables(2.3M)18.79M(2.79M)(292K)(2.28M)
Other Working Capital(899K)(9.64M)(12.03M)(3.88M)21.73M
Other Non-Cash Items4.36M5.16M(1.61M)(6.23M)7.96M
Operating Cash Flow218.88M(207.49M)(218.41M)(173.13M)(123.96M)
Capital Expenditures(84.18M)(30.72M)(9.96M)(2.44M)(2.41M)
Acquisitions (Net)(4.99M)0000
Purchases of Investments(498.14M)(184.88M)(86.56M)(190.14M)(332.63M)
Sales of Investments175.68M203.67M287.47M290.24M319.11M
Other Investing Activities4.99M005.78M62K
Investing Cash Flow(406.64M)(11.93M)190.94M103.45M(15.87M)
Debt Repayment00000
Common Stock Issued218.21M1.74M6.7M131.07M1.01M
Common Stock Repurchased0001.19M0
Dividends Paid00000
Other Financing Activities(22.96M)(30.58M)(41.67M)(39.58M)115.76M
Financing Cash Flow195.25M(28.84M)(34.97M)92.68M116.77M
Effect of Forex Changes00000
Net Change in Cash7.48M(248.26M)(62.43M)23M(23.06M)
Free Cash Flow134.7M(238.21M)(228.37M)(175.56M)(126.38M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$193.9M
+ D&A$15.6M
+ Stock-Based Comp$34.6M
+ Deferred Tax$0
+ Working Capital$11.8M
+ Other Non-Cash$8.0M
= Operating Cash Flow-$124.0M
- Capex-$2.4M
= Free Cash Flow-$126.4M

Analysis

FY2025 free cash flow is -$126.4M. FCF conversion is 65.2% of net income. Operating cash flow was -$124.0M, with capex of -$2.4M. The largest bridge item is Stock-Based Comp at $34.6M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
SC 13GSC 13G filingNov 10, 2026
10-QQuarterly reportNov 5, 2026
8-KCurrent reportNov 5, 2026
4Statement of changes in beneficial ownershipNov 3, 2026
4Statement of changes in beneficial ownershipNov 3, 2026

Does RGNX generate free cash flow?

REGENXBIO Inc. (RGNX) generated -$126.38M of free cash flow in fiscal 2025.

How much operating cash flow does RGNX produce?

Operating cash flow was -$123.96M, before capital expenditures of $2.41M.